1
|
Conroy S, Kindon ND, Glenn J, Stoddart LA, Lewis RJ, Hill SJ, Kellam B, Stocks MJ. Synthesis and Evaluation of the First Fluorescent Antagonists of the Human P2Y 2 Receptor Based on AR-C118925. J Med Chem 2018; 61:3089-3113. [PMID: 29558126 PMCID: PMC6026847 DOI: 10.1021/acs.jmedchem.8b00139] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
![]()
The
human P2Y2 receptor (hP2Y2R)
is a G-protein-coupled receptor that shows promise as a therapeutic
target for many important conditions, including for antimetastatic
cancer and more recently for idiopathic pulmonary fibrosis. As such,
there is a need for new hP2Y2R antagonists
and molecular probes to study this receptor. Herein, we report the
development of a new series of non-nucleotide hP2Y2R antagonists, based on the known, non-nucleotide hP2Y2R antagonist AR-C118925 (1),
leading to the discovery of a series of fluorescent ligands containing
different linkers and fluorophores. One of these conjugates, 98, displayed micromolar affinity for hP2Y2R (pKd = 6.32 ± 0.10, n = 17) in a bioluminescence-energy-transfer (BRET) assay.
Confocal microscopy with this ligand revealed displaceable membrane
labeling of astrocytoma cells expressing untagged hP2Y2R. These properties make 98 one of the
first tools for studying hP2Y2R distribution
and organization.
Collapse
Affiliation(s)
- Sean Conroy
- School of Pharmacy, Centre for Biomolecular Sciences , University Park Nottingham , Nottingham NG7 2RD , U.K
| | - Nicholas D Kindon
- School of Pharmacy, Centre for Biomolecular Sciences , University Park Nottingham , Nottingham NG7 2RD , U.K
| | - Jacqueline Glenn
- Division of Physiology, Pharmacology & Neuroscience, Medical School , University of Nottingham , Nottingham NG7 2UH , U.K.,Centre of Membrane Proteins and Receptors , University of Birmingham and University of Nottingham , the Midlands NG7 2UH , U.K
| | - Leigh A Stoddart
- Division of Physiology, Pharmacology & Neuroscience, Medical School , University of Nottingham , Nottingham NG7 2UH , U.K.,Centre of Membrane Proteins and Receptors , University of Birmingham and University of Nottingham , the Midlands NG7 2UH , U.K
| | - Richard J Lewis
- Medicinal Chemistry, Respiratory, Inflammation and Autoimmunity, IMED Biotech Unit , AstraZeneca , Mölndal, Gothenburg 431 83 , Sweden
| | - Stephen J Hill
- Division of Physiology, Pharmacology & Neuroscience, Medical School , University of Nottingham , Nottingham NG7 2UH , U.K.,Centre of Membrane Proteins and Receptors , University of Birmingham and University of Nottingham , the Midlands NG7 2UH , U.K
| | - Barrie Kellam
- School of Pharmacy, Centre for Biomolecular Sciences , University Park Nottingham , Nottingham NG7 2RD , U.K.,Centre of Membrane Proteins and Receptors , University of Birmingham and University of Nottingham , the Midlands NG7 2UH , U.K
| | - Michael J Stocks
- School of Pharmacy, Centre for Biomolecular Sciences , University Park Nottingham , Nottingham NG7 2RD , U.K
| |
Collapse
|
2
|
Silva RO, de Oliveira AS, Nunes Lemes LF, de Camargo Nascente L, Coelho do Nascimento Nogueira P, Silveira ER, Brand GD, Vistoli G, Cilia A, Poggesi E, Buccioni M, Marucci G, Bolognesi ML, Romeiro LAS. Synthesis and structure-activity relationships of novel arylpiperazines as potent antagonists of α1-adrenoceptor. Eur J Med Chem 2016; 122:601-610. [PMID: 27448917 DOI: 10.1016/j.ejmech.2016.06.052] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2016] [Revised: 06/10/2016] [Accepted: 06/28/2016] [Indexed: 12/01/2022]
Abstract
Arylpiperazines 2-11 were synthesized, and their biological profiles at α1-adrenergic receptors (α1-ARs) assessed by binding assays in CHO cells expressing human cloned subtypes and by functional experiments in isolated rat vas deferens (α1A), spleen (α1B), and aorta (α1D). Modifications at the 1,3-benzodioxole and phenyl phamacophoric units resulted in the identification of a number of potent compounds (moderately selective with respect to the α1b-AR), in binding experiments. Notably, compound 7 (LDT451) showed a subnanomolar pKi of 9.41 towards α1a-AR. An encouragingly lower α1B-potency was a general trend for all the series of compounds, which showed α1A/D over α1B selectivity in functional assays. If adequately optimized, such peculiar selectivity could have relevance for a potential LUTS/BPH therapeutic application.
Collapse
Affiliation(s)
- Renata Oliveira Silva
- Department of Pharmacy, Health Sciences Faculty, University of Brasília, Campus Universitário Darcy Ribeiro, 70910-900, Brasília, DF, Brazil; LADETER, Catholic University of Brasília, QS 07, Lote 01, EPCT, Águas Claras, 71966-700, Brasília, DF, Brazil
| | - Andressa Souza de Oliveira
- Department of Pharmacy, Health Sciences Faculty, University of Brasília, Campus Universitário Darcy Ribeiro, 70910-900, Brasília, DF, Brazil; LADETER, Catholic University of Brasília, QS 07, Lote 01, EPCT, Águas Claras, 71966-700, Brasília, DF, Brazil
| | - Laís Flávia Nunes Lemes
- LADETER, Catholic University of Brasília, QS 07, Lote 01, EPCT, Águas Claras, 71966-700, Brasília, DF, Brazil
| | - Luciana de Camargo Nascente
- LADETER, Catholic University of Brasília, QS 07, Lote 01, EPCT, Águas Claras, 71966-700, Brasília, DF, Brazil
| | | | - Edilberto R Silveira
- Departament of Organic and Inorganic Chemistry, Federal University of Ceará, 60021-970, Fortaleza, CE, Brazil
| | - Guilherme D Brand
- Chemistry Institute, University of Brasília, Campus Universitário Darcy Ribeiro, 70910-900, Brasília, DF, Brazil
| | - Giulio Vistoli
- Department of Pharmaceutical Science, University of Milan, Via Mangiagalli 25, 20133, Milan, Italy
| | - Antonio Cilia
- Drug Discovery Department, Recordati S.p.A, Via Civitali 1, 20148, Milan, Italy
| | - Elena Poggesi
- Drug Discovery Department, Recordati S.p.A, Via Civitali 1, 20148, Milan, Italy
| | - Michela Buccioni
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, via S. Agostino, 1, I-62032, Camerino, Italy
| | - Gabriella Marucci
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, via S. Agostino, 1, I-62032, Camerino, Italy
| | - Maria Laura Bolognesi
- Department of Pharmacy and Biotechnology, University of Bologna, Via Belmeloro 6, 40126, Bologna, Italy.
| | - Luiz Antonio Soares Romeiro
- Department of Pharmacy, Health Sciences Faculty, University of Brasília, Campus Universitário Darcy Ribeiro, 70910-900, Brasília, DF, Brazil; LADETER, Catholic University of Brasília, QS 07, Lote 01, EPCT, Águas Claras, 71966-700, Brasília, DF, Brazil.
| |
Collapse
|
3
|
Gupta S, Pandey D, Mandalapu D, Bala V, Sharma V, Shukla M, Yadav SK, Singh N, Jaiswal S, Maikhuri JP, Lal J, Siddiqi MI, Gupta G, Sharma VL. Design, synthesis and biological profiling of aryl piperazine based scaffolds for the management of androgen sensitive prostatic disorders. MEDCHEMCOMM 2016. [DOI: 10.1039/c6md00426a] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Twenty-six piperazine derivatives were synthesized and findings revealed that compound9ais promising candidate for management of prostatic disorders.
Collapse
|
4
|
Chen H, Xu F, Liang X, Xu BB, Yang ZL, He XL, Huang BY, Yuan M. Design, synthesis and biological evaluation of novel arylpiperazine derivatives on human prostate cancer cell lines. Bioorg Med Chem Lett 2015; 25:285-7. [DOI: 10.1016/j.bmcl.2014.11.049] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2014] [Revised: 11/12/2014] [Accepted: 11/18/2014] [Indexed: 01/16/2023]
|
5
|
Chen H, Liang X, Xu F, Xu B, He X, Huang B, Yuan M. Synthesis and cytotoxic activity evaluation of novel arylpiperazine derivatives on human prostate cancer cell lines. Molecules 2014; 19:12048-64. [PMID: 25120056 PMCID: PMC6271825 DOI: 10.3390/molecules190812048] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2014] [Revised: 08/04/2014] [Accepted: 08/06/2014] [Indexed: 12/13/2022] Open
Abstract
A series of novel arylpiperazine derivatives was synthesized. The in vitro cytotoxic activities of all synthesized compounds against three human prostate cancer cell lines (PC-3, LNCaP, and DU145) were evaluated by a CCK-8 assay. Compounds 9 and 15 exhibited strong cytotoxic activities against LNCaP cells (IC50 < 5 μM), and compound 8 (IC50 = 8.25 μM) possessed the most potent activity against DU145 cells. However, these compounds also exhibited cytotoxicity towards human epithelial prostate normal cells RWPE-1. The structure–activity relationship (SAR) of these arylpiperazine derivatives was also discussed based on the obtained experimental data.
Collapse
Affiliation(s)
- Hong Chen
- Pharmaceutical Research Center, Guangzhou Medical University, 195# Dongfengxi Road, Guangzhou 510182, China.
| | - Xue Liang
- Pharmaceutical Research Center, Guangzhou Medical University, 195# Dongfengxi Road, Guangzhou 510182, China.
| | - Fang Xu
- Pharmaceutical Research Center, Guangzhou Medical University, 195# Dongfengxi Road, Guangzhou 510182, China.
| | - Bingbing Xu
- Pharmaceutical Research Center, Guangzhou Medical University, 195# Dongfengxi Road, Guangzhou 510182, China.
| | - Xuelan He
- Pharmaceutical Research Center, Guangzhou Medical University, 195# Dongfengxi Road, Guangzhou 510182, China.
| | - Biyun Huang
- Pharmaceutical Research Center, Guangzhou Medical University, 195# Dongfengxi Road, Guangzhou 510182, China.
| | - Mu Yuan
- Pharmaceutical Research Center, Guangzhou Medical University, 195# Dongfengxi Road, Guangzhou 510182, China.
| |
Collapse
|
6
|
Louie AS, Vasdev N, Valliant JF. Preparation, Characterization, and Screening of a High Affinity Organometallic Probe for α-Adrenergic Receptors. J Med Chem 2011; 54:3360-7. [PMID: 21428421 DOI: 10.1021/jm2001162] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Anika S. Louie
- Department of Chemistry and Chemical Biology, McMaster University, 1280 Main Street W., Hamilton, Ontario, L8S 4M1, Canada
| | - Neil Vasdev
- Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto, 250 College Street, Toronto, Ontario, M5T 1R8, Canada
| | - John F. Valliant
- Department of Chemistry and Chemical Biology, McMaster University, 1280 Main Street W., Hamilton, Ontario, L8S 4M1, Canada
- Department of Medical Physics and Applied Radiation Sciences, McMaster University, 1280 Main Street W., Hamilton, Ontario, L8S 4M1, Canada
| |
Collapse
|
7
|
Zhao X, Yuan M, Huang B, Ji H, Zhu L. Ligand-based pharmacophore model of N-Aryl and N-Heteroaryl piperazine alpha 1A-adrenoceptors antagonists using GALAHAD. J Mol Graph Model 2010; 29:126-36. [PMID: 20538497 DOI: 10.1016/j.jmgm.2010.05.002] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2009] [Revised: 05/06/2010] [Accepted: 05/07/2010] [Indexed: 10/19/2022]
Abstract
Computer aided drug discovery for selective antagonism effects on alpha(1A) subtypes of G-protein coupled receptors are important in the treatment of benign prostatic hyperplasia (BPH). Ligand-based pharmacophore models of N-Aryl and N-Heteroaryl piperazine alpha(1A)-antagonists were developed using two separate training sets. Pharmacophore models were generated using the flexible align method within the GALAHAD module, implemented in SYBYL8.1 software. The most significant pharmacophore hypothesis, characterized by the conflicting demands of maximizing pharmacophore consensus, maximizing steric consensus, and minimizing energy, consisted of one positive nitrogen center, one donor atom center, two acceptor atom centers, and two hydrophobic groups. The most active compound in each class training set showed a good fit with all features of the pharmacophore proposed. The resulting models also had something in common with the hypothesis using the Catalyst software reported in other publications. These alpha(1A) pharmacophore models could predict compounds well, both in the training set and the test set. The pharmacophore models were also validated by an external dataset using a portion of the ZINC database. A 3D-QSAR model using the pharmacophore model to align the compounds was established in this study. The CoMFA model with the cross-validated q(2) value of 0.735 revealed that the model was valid. Our research provides a valuable tool for designing new therapeutic compounds with desired biological activity.
Collapse
Affiliation(s)
- Xin Zhao
- Pharmaceutical Research Center, Guangzhou Medical College, Guangzhou, Guangdong 510182, China
| | | | | | | | | |
Collapse
|
8
|
Jain KS, Bariwal JB, Kathiravan MK, Phoujdar MS, Sahne RS, Chauhan BS, Shah AK, Yadav MR. Recent advances in selective α1-adrenoreceptor antagonists as antihypertensive agents. Bioorg Med Chem 2008; 16:4759-800. [DOI: 10.1016/j.bmc.2008.02.091] [Citation(s) in RCA: 77] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2008] [Revised: 02/27/2008] [Accepted: 02/27/2008] [Indexed: 11/29/2022]
|
9
|
MacDougall IJA, Griffith R. Selective pharmacophore design for α1-adrenoceptor subtypes. J Mol Graph Model 2006; 25:146-57. [PMID: 16406718 DOI: 10.1016/j.jmgm.2005.12.001] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2005] [Revised: 12/01/2005] [Accepted: 12/01/2005] [Indexed: 11/29/2022]
Abstract
Alpha1-adrenoceptors are G-protein coupled receptors found in a variety of vascular tissues and responsible for vasoconstriction. Selectivity for each of the three subtypes is an important consideration in drug design in order to minimise the possibility of side effects. Using Catalyst we developed ligand-based pharmacophores from alpha(1a,b,d)-selective antagonists available in the literature using three separate training sets. Four-feature pharmacophores were developed for the alpha(1a) and alpha(1b) subtype-selective antagonists and a five-feature pharmacophore was developed for the alpha(1d) subtype-selective antagonists. The alpha(1a) pharmacophore represents both class I and II compounds with good predictivity for other compounds outside the training set as well. The alpha(1b) pharmacophore best predicts the activity of prazosin analogues as these make up the majority of alpha(1b)-selective antagonists. Unexpectedly, no positive ionisable feature was incorporated in the alpha(1b) pharmacophore. The alpha(1d) pharmacophore was based primarily on one structural class of compounds, but has good predictivity for a heterogeneous test set. Preliminary docking studies using AutoDock and optimised alpha1-adrenoceptor homology models, conducted with the antagonists prazosin (32) and 66, showed good agreement with the findings from the pharmacophores.
Collapse
Affiliation(s)
- Iain J A MacDougall
- School of Environmental and Life Sciences, The University of Newcastle, Australia
| | | |
Collapse
|
10
|
|
11
|
Lopez FJ, Arias L, Chan R, Clarke DE, Elworthy TR, Ford APDW, Guzman A, Jaime-Figueroa S, Jasper JR, Morgans DJ, Padilla F, Perez-Medrano A, Quintero C, Romero M, Sandoval L, Smith SA, Williams TJ, Blue DR. Synthesis, pharmacology and pharmacokinetics of 3-(4-aryl-piperazin-1-ylalkyl)-uracils as uroselective alpha1A-antagonists. Bioorg Med Chem Lett 2003; 13:1873-8. [PMID: 12749888 DOI: 10.1016/s0960-894x(03)00305-6] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Predominance in the urethra and prostate of the alpha(1A)-adrenoceptor subtype, which is believed to be the receptor mediating noradrenaline induced smooth muscle contraction in these tissues, led to the preparation of alpha(1A)-selective antagonists to be tested as uroselective compounds for the treatment of benign prostatic hyperplasia. Thus, a number of selective alpha(1A)-adrenoceptor antagonists were synthesized and assayed in vitro for potency and selectivity. Dog pharmacokinetic parameters of 12 (RO700004) and its metabolite 40 (RO1104253) were established. The relative selectivity of intravenously administered 12, 40 and standard prazosin to inhibit hypogastric nerve stimulation-induced increases in intraurethral prostatic pressure versus phenylephrine-induced increases in diastolic blood pressure in anesthetized dogs was 76, 71 and 0.6, respectively.
Collapse
Affiliation(s)
- F J Lopez
- Roche Bioscience, 3431 Hillview Ave, Palo Alto, CA 94304, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|